8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
AbbVie expects $1.3B pre-tax acquired IPR&D & milestones expense in Q4 2025, an unfavorable impact of…
Filed with the SEC on · Summarized by InvestorsBot
AbbVie expects $1.3B pre-tax acquired IPR&D & milestones expense in Q4 2025, an unfavorable impact of $0.71 on both GAAP and adjusted diluted EPS; Q4 results are preliminary and subject to close. 📉 $ABBV #earnings #pharma
Including the Q4 charge, AbbVie’s 2025 adjusted diluted EPS guidance is $9.90–$9.94; Q4 adjusted diluted EPS guidance is $2.61–$2.65. Prior guidance had excluded potential post‑Q3 IPR&D/milestones. 📊 $ABBV #guidance #investing
AbbVie furnished Exhibit 99.1 with these estimates; company notes figures are preliminary and may change and that it does not forecast IPR&D/milestones due to timing uncertainty. 💼 $ABBV #SEC #corporate